Controlling T cells to improve long-term heart transplant outcomes
Mechanisms and Therapeutic Targeting of T cell Regulation in Heart Allograft Recipient Monkeys
Tests new ways to calm the immune system so people who get heart transplants have fewer rejections and better long-term results.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11262898 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are using monkey heart transplant models to try treatments that lower harmful reactive oxygen species and block inflammatory signals such as IL-6, IL-7, and IL-15 that help memory T cells survive. They will also test giving regulatory T cells (Tregs) that are expanded or engineered to control donor-reactive memory T cells that resist standard immunosuppression. The team will examine effects on graft blood vessel cells, immune cell behavior, and whether these approaches prevent chronic rejection in the animals. The goal is to build safety and efficacy data that could support future human trials for heart transplant recipients.
Who could benefit from this research
Good fit: People who have had a heart transplant or are awaiting one—especially those at high risk for immune-driven chronic rejection—would be the likely candidates for related future human trials.
Not a fit: People without heart transplants, those whose graft problems are not immune-mediated, or patients who cannot receive immune-modifying treatments are unlikely to benefit from this research.
Why it matters
Potential benefit: Could reduce chronic rejection and the need for lifelong high-dose immunosuppression, improving graft and patient survival after heart transplant.
How similar studies have performed: Blocking IL-6 and testing regulatory T cell therapies have shown promise in animal studies and early human work, but overcoming immunosuppression-resistant memory T cells remains a difficult and only partially proven approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Ezzelarab, Mohamed B — University of Pittsburgh at Pittsburgh
- Study coordinator: Ezzelarab, Mohamed B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.